Compare Endeavour Silver Corp (EXK) vs 10X Genomics Inc (TXG) Price & Performance

Endeavour Silver (EXK) trades at $10.60, up 3.52% today, with strong technical momentum and bullish analyst sentiment. The company shows improving fundamentals with Q1 2026 earnings beating expectations and revenue growth projected from $468M in 2025 to $737M in 2026. Recent news highlights operational expansion, including the Terronera mine ramp-up and a new $25M credit facility, supporting future growth in silver and gold production.

Outlook is positive with 78.6% analyst buy ratings and a $15.50 consensus price target offering 46% upside. Key risks include execution of mine expansions, commodity price volatility, and the company's transition to profitability after a 2025 net loss. The stock presents a growth opportunity if operational targets are met, though investors should monitor quarterly earnings consistency.

TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.

Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.